标题：Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence
作者：Xu, Cuiping; Xie, Jian; Liang, Ning; Wang, Junrong; Qiao, Lili; Luo, Hui; Zhang, Jing Xin; Zhang, Jiandong
作者机构：[Xu, Cuiping; Xie, Jian; Liang, Ning; Qiao, Lili; Zhang, Jiandong] Shandong Univ, Qianfoshan Hosp, Dept Radiat Oncol, Jinan 250014, Shandong, Peoples 更多
通讯作者地址：[Zhang, JD]Shandong Univ, Qianfoshan Hosp, Dept Radiat Oncol, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.
来源：JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
关键词：Gastric cancer; oligometastatic recurrence; radiochemotherapy; XELOX
摘要：Purpose: The aim of this study was to retrospectively observe gastric adenocarcinoma patients with postoperative oligometastatic recurrence and investigated the effects of concurrent involved-field radiotherapy (RT) and XELOX on progression-free survival (PFS).; Patients and Methods: From 2008 to 2011, 246 patients underwent curative resection of gastric carcinoma was enrolled. A retrospective review was performed on 34 patients with distant recurrence. Among them, 19 patients were oligometastases patients, where 13 patients received involved-field RT with a dose of 40-60 Gy by an intensity-modulated RT technique and concurrent XELOX chemotherapy, four patients were treated with XELOX chemotherapy alone (oxaliplatin 130 mg/m(2), capecitabine 1000 mg/m(2), twice daily, 3 week each cycle), and two patients with only brain metastasis were not included in the analysis.; Results: The median PFS was 11 months in the 13 oligometastatic patients who received concurrent involved-field RT and XELOX. The oligometastatic patients receiving concurrent radiochemotherapy trended toward a better median PFS when compared with those receiving chemotherapy alone.; Conclusions: For patients with postoperative oligometastatic recurrence, concurrent involved-field RT and XELOX showed better responses and was a choice for first-line treatment.